Use the trial balance and additional information given in Case 5.3 in Chapter 5, and prepare the balance sheet of Cipla Limited as on 31st March 2017.

Case 5.3

Cipla is a leading global pharmaceutical company, dedicated to high­quality, branded and generic medicines. We are trusted by healthcare professionals and patients across geographies. Cipla was founded in the year 1935 and has presence in 80 countries. The company has over 23,000 employees and a global revenue exceeding USD 2.2 billion. 

From the following trial balance and the additional information for the company, you are required to prepare the statement of profit and loss for the company for the year ended 31st March 2017.

Additional Information

1. Closing inventories as on 31st March 2017 consists of 

2. Provide depreciation on property, plant and equipment: ₹ 465 crore 

3. Amortise intangible assets: ₹ 35 crore. 

4. Make provision for doubtful trade receivables : ₹ 33 crore 

Transcribed Image Text:

Particulars Bank balance other than cash and cash equivalents Capital work-in-progress Cash and cash equivalents Commission on sales Contractual services expenses Contribution to pf and other funds Csr expenditure Current investments Current loans Current tax expenses Current tax assets Deferred tax assets Employee stock option expense Freight and forwarding Impairment of investment Income tax on oci Intangible assets Intangible assets under development Interest expense Manufacturing expenses Non-current investments Non-current loans Opening stock-raw material and packing material Amount 14 540 45 234 164 71 28 638 10 311 192 60 22 158 251 4 202 15 39 443 3,648 216 1,303 Particulars Accumulated amortisation Accumulated depreciation Current borrowings from banks Deferred tax credit General reserve OCI will not be classified to profit and loss Other current financial liabilities Other current liabilities Other financial liabilities - non current Other income Other non-current liabilities Other operating income Outstanding employee stock options Provision for doubtful trade receivables Provisions-current Provisions-non current Retained earnings Revenue from sales of products Securities premium Share capital Trade payables Amount 27 389 324 99 3,142 11 456 230 45 130 80 337 59 97 248 126 6,951 10,637 1,505 161 1,298